LOS ANGELES--(BUSINESS WIRE)--CytRx Corporation (NASDAQ:CYTR) today announced that it has initiated screening volunteers in its Phase IIb clinical trial with arimoclomol for the treatment of Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig’s disease). The double-blind, placebo-controlled trial is expected to require nine months to complete enrollment of approximately 390 ALS volunteers at 30 to 40 U.S. and Canadian clinical sites, and will evaluate the safety and efficacy of 400 mg arimoclomol administered orally three times daily for a nine-month period. In order to maximize the amount of long-term safety and efficacy data from this trial, CytRx will continue double-blind arimoclomol administration for an additional nine months after collection of primary endpoint data to collect additional data on secondary endpoints.
